High temperature ultrasound thermal therapy using interstitial and external approaches is becoming increasingly acceptable as a minimally invasive clinical treatment for cancerous and benign disease. The diameter of an interstitial applicator can influence its clinical practicality and effectiveness as well as application site. The purpose of this study was to determine whether the use of larger ultrasound transducers and the inherent increase in applicator size could be justified by potentially producing larger lesion diameters. Four applicator configurations and sizes were studied using ex vivo tissue experiments in liver and beef and using acoustic and biothermal simulations. Cathetercooled and internally cooled applicators with outer diameters between 2.2 and 4.0 mm produced 3.5 to 5.0 cm diameter lesions in ex vivo liver and 3.0 to 3.5 cm lesions in ex vivo beef muscle with 20-40 W/cm applied for 10 min. Larger applicators produced lesions with radial penetration depths superior to their smaller counterparts at power levels in the 20-40 W/cm range. The higher cooling rates along the outer surface of the larger diameter applicators due to their greater surface area was a dominant factor in increasing lesion size. The higher cooling rates pushed the maximum temperature farther from the applicator surface and reduced the formation of high acoustic attenuation tissue zones. Applicator configuration and frequency ͑6.7-8.2 MHz͒ had less influence on lesion size than diameter in the ranges studied. Acoustic and biothermal simulations matched the experimental data well and were applied to model these applicators within sites of clinical interest such as prostate, uterine fibroid, brain, and normal liver. Lesions of 3.9 to 4.7 cm diameter were predicted for moderately perfused tissues such as prostate and fibroid and 2.8 to 3.2 cm for highly perfused tissues such as normal liver. In sites such as uterine fibroid where larger applicators placed using an endoscopic approach could be tolerated, treatment volume increases of 37% were predicted for an applicator diameter increase from 2.4 to 4.0 mm.
I. INTRODUCTION
High-temperature thermal therapy is becoming increasingly acceptable as a minimally invasive approach for the clinical treatment of cancerous and benign disease. Interstitial, intracavitary, and external approaches are commonly employed using heating modalities such as ultrasound, microwave, laser, and radio-frequency currents. Some recent clinical examples include the treatment of prostate benign hyperplasia 1-3 and cancer, 4 -6 fibroids and malignant breast disease, 7 unresectable liver tumors, 8 and alleviation of discogenic low back pain. 9 Interstitial approaches can be useful for treating large, deep-seated volumes of tissue in a relatively short time ͑1-20 min͒, with applicator size and treatment volume varying significantly with the heating modality. Some of the smallest applicators include individual interstitial laser fibers of less than a millimeter in diameter, which have been shown to produce approximately 10 mm outer diameter ͑OD͒ lesions in breast, 10 and uncooled microwave applicators of 1.6 mm in diameter, which have produced 26 mm OD lesions in liver. 11 Cooled laser applicators with diameters of less than 2 mm have been shown to produce over 20 mm OD lesions in liver in 20 min heats. 12 Single, cooled radio-frequency, microwave, and cylindrical ultrasound applicators with diameters from 1.5 to 2.2 mm have produced up to 36 mm OD lesions in in vivo liver and up 45 mm OD in ex vivo liver experiments. 8, 13 On the larger end of the applicator size spectrum, planar and focused ͑individual, curved͒ ultrasound transducers inside 3.8 -5 mm OD applicators have been shown to produce discrete in vitro lesions 3-5 mm wide which extend 15-20 mm in radius. 14, 15 Repeated, sequential heats made by rotating these applicators can produce lesions somewhat resembling those from cylindrical sources. Devices considered too large for interstitial use have been employed as intracavitary applicators for transurethral ultrasound thermal therapy. Applicators with an outer diameter of 6 -10 mm have produced directional 2 cm radial lesions in prostate. 16 -18 An important feature of ultrasound applicators is that the axial heating profile can be dynamically controlled by using multiple transducers along the length of a single applicator. The energy output from each transducer is collimated and controllable, and cylindrical transducers can be sectored to give angular or directional power output. With cooled interstitial ultrasound applicators, in particular those utilizing cylindrical transducers, it is possible to increase or decrease the applicator outer diameter by using larger or smaller transducers. The lower limit of applicator size is constrained by manufacturing capabilities and cooling flow rates. Altering the cooling water flow scheme can also influence the size of the transducer relative to the outer diameter of the applicator. The purpose of this study is to determine whether the use of larger ultrasound transducers and the inherent increase in applicator size can be justified by potentially producing larger diameter lesions. In addition, this study hopes to identify potential site-specific differences in the use of applicators of varying diameter and cooling configurations.
II. MATERIALS AND METHODS

A. Ultrasound applicators
Four different applicator configurations were used to complete this study, two catheter cooled ͑CC͒ and two internally cooled, direct coupled ͑ICDC͒ applicators. Table I summarizes the key parameters of the applicators used for the experimental and theoretical studies, and Fig. 1 shows an image of each applicator configuration. All applicator configurations consisted of a variable number of cylindrical, piezoceramic transducers ͑PZT-4 tubes, Boston Piezooptics͒ mounted within a biocompatible plastic casing. For the 2.4 mm OD CC applicators, the transducers were positioned within 13 g Celcon catheters ͑Best Industries͒. This allowed water to circulate inside the catheter and along the outer surface of the transducers. Water cooling kept the temperature of the active transducers down and cooled the adjacent tissue, pushing the maximum temperature deeper into the tissue while heating. Additional detail on the specifics of 2.4 mm OD CC applicators is given elsewhere. 19, 20 The 4.0 mm OD CC applicators were similar to the smaller 2.4 mm OD CC applicators, but with larger catheters custom made in house using Polyester ͑PET, Advanced Polymers͒ and Polyimide ͑HV Technologies͒ tubing. The PET served as an acoustic window in the Polyimide catheter over the transducers, as shown in Fig. 1 . The catheter had an OD of 4.0 mm, and the PET section had a wall thickness of 0.002 in ͑50 m͒.
The internally cooled applicators did not employ an external catheter and were coupled directly to the tissue through a thin biocompatible plastic layer. The transducers were cooled by water circulating along their inside surface. Both the 2.2 and 4.0 mm OD ICDC applicators implemented a design strategy similar to that described in detail by Deardorff et al., 21 but with the addition of an internal polymer spline to center the transducer over the inner cooling water lumen and to provide additional structural support. Since the cooling water circulated along the inner surface of the transducers in ICDC applicators, the transducer OD for the ICDC applicators could be larger than the transducer OD for CC applicators of the same applicator OD, as seen in Table I .
B. Experimental lesion studies
A series of ultrasound lesions were made using these CC and ICDC applicators in beef muscle from a grocery butcher and bovine liver approximately 3 h from slaughter as ex vivo tissue models. After degassing for 1 h, the tissue samples were placed in a 37°C saline bath and allowed to reach equilibrium ͑approximately 1-2 h͒. Each sample was at least 15 cm in diameter to minimize boundary effects on lesion size. After the appropriate interstitial applicator was inserted into the center of the sample and the cooling water flow ͑10°C, flow rates given in Table I͒ turned on, we applied electrical power ͑500-009 RF Generator, Advanced Surgical Systems, Inc.͒ to the applicator for a total of 10 min. Within 10 s of the end of the heating duration, the cooling water flow was turned off and the applicator was removed. The tissue sample remained in the saline bath for at least 5 min after the applicator was removed to allow thermal dose to accumulate from energy already deposited in the tissue. We then sliced the tissue samples down the center of the lesion and measured the maximum diameter of visible coagulation ͑discoloration͒. The average of three separate heating trials was used for each data point.
C. Acoustic and biothermal model
To compare results to the ex vivo experimental studies and to simulate clinical use in vivo, we implemented a biothermal model of these ICDC and CC applicators. Full development of this model is described in detail and experimentally verified elsewhere. 22 The model is based on the Pennes Bioheat Transfer equation, 23 which is given as Eq. ͑1͒:
The terms t and c t are the density ͑kg/m 3 ͒ and heat capacity ͑J/kg•°C͒ of the tissue, respectively. They were assumed to be independent of the partial derivative of time. ͒ from the ultrasound applicator. For this study we utilized a 2-D rϪz cylindrical coordinate system. Since these applicators were symmetric in angle ͑͒, this was equivalent to a full 3-D model for determining radial lesion size. Radial lesion dimensions were measured in the lesion centerline.
The power deposition from a cylindrical ultrasound source can be approximated by
where ␣ is the ultrasound absorption coefficient ͑Np/m͒, I s is the ultrasound intensity along the surface of the transducer ͑W/m 2 ͒, r is the radial distance from the center of the transducer ͑m͒, and r 0 is the radius of the transducer ͑m͒. The term is the ultrasound attenuation coefficient ͑Np/m͒. In this work we assumed that the absorption ␣ was proportional to the ultrasound attenuation .
Due to inefficiencies in the transducer, not all of the applied electrical energy will be emitted as acoustic energy. The remaining energy is primarily converted into heat within the transducer, with a deposition rate given by
with representing the transducer efficiency. Thermal energy in the transducer is removed through convective heat transfer into the cooling water along the the outer transducer surface for CC applicators or inner transducer surface for ICDC applicators. The amount of energy transferred through the convective boundary per unit time and volume is given by
where h is the convective heat transfer coefficient ͑W/m 2 •K͒. A is the surface area ͑m 2 ͒, V is the volume ͑m 3 ͒, and T w is the constant temperature of the cooling water ͑°C͒. A constant temperature boundary (T B ) was applied along the outer edges of the model (T B ϭT b ).
The temperature distributions were calculated using a finite difference numerical solution of Eqs. ͑1͒-͑4͒, imposing the above boundary conditions. 26 The node spacing varied from ⌬rϷ0.02 mm near the transducer to ⌬rϷ0.5 mm farther out in the tissue. The numerical solution utilized the Crank-Nicholson method, 27 a mixed implicit and explicit integration technique that improved numerical stability of the tight grid spacing without a very small time step.
The model also incorporated dynamic treatment of blood perfusion and acoustic attenuation as a function of thermal dose. Thermal dose is a method of quantifying the effect of temperature and duration of heating on tissue. Sapareto and Dewey 28, 29 give an expression for numerically calculating the iso-effect thermal dose,
In this expression, t 43 is the equivalent time ͑min͒ at 43°C, and T t is the average temperature during ⌬t ͑min͒. The value of R was 0.25 for temperatures lower than 43°C and 0.5 for temperatures above 43°C. Differences between applicator types and configurations were studied using simulations of treatments in sites of clinical interest and in ex vivo tissue models. The ex vivo simulations were performed with parameters matching the corresponding experimental conditions ͑Tables I and II͒ to allow for further verification of the acoustic and biothermal model. In addition, simulations of the same applicators as used in the ex vivo experiments were run in clinical sites of interest ͑Table II͒ to emulate in vivo performance. The results of these simulations were designed to approximate expected lesion sizes in clinically relevant tissues and to compare the relative performance of each applicator configuration.
During heating, the acoustic attenuation and perfusion have been shown to change as a function of thermal dose, measured up to temperatures of 70-75°C. [30] [31] [32] The change in acoustic attenuation with thermal dose for the in vivo simulations was modeled as a three-part process based on this data. The attenuation was modeled as not changing from normal tissue values at doses below t 43 ϭ10 2 min, varying linearly with the log of thermal dose from t 43 ϭ10 2 to 10 7 min, and constant at coagulated values above t 43 ϭ10 7 min. 30 Perfusion was modeled as constant at normal values up to t 43 ϭ300 min, at which point it went to zero. 33 Inclusion of these dynamic changes allowed for more accurate simulation of in vivo experimental conditions.
In order to more accurately match the ex vivo experimental results, modifications were made to the above attenuation model. For the ex vivo simulations, the attenuation values reached a threshold at a higher value of thermal dose. Based on in-house transmission measurements of attenuation in lesions from ultrasound applicators and backed by recent published attenuation studies, 34, 35 the attenuation was modeled as varying linearly with the log of thermal dose from t 43 ϭ10 2 to 10 15 min. The attenuations reached at t 43 ϭ10 15 min, which occurred at temperature higher than the maximum reached in the Damianou attenuation study, 30 were greater that those at t 43 ϭ10 7 min. These larger attenuation ranges were used only for the ex vivo beef and liver simulations, where experimental data at very high thermal doses was available. The attenuation ranges for these tissues, as given in Table II, correspond to the lowest (t 43 Ϲ10 2 ) and highest (t 43 м10
15 ) values. For the in vivo simulations, the best estimates from the existing literature were used, with the attenuation ranges for these tissues as given in Table II corresponding to the lowest (t 43 Ϲ10
2 ) and highest (t 43 м10 7 ) values.
For all simulations, a lethal dose of t 43 ϭ600 min was chosen to define coagulation and to compare with experimental results. Previous studies have shown that approximately t 43 ϭ250 to 300 min correlates to visible coagulation. 6, 36, 37 The estimate of t 43 ϭ600 min is slightly more conservative, but, due to the exponential nature of the thermal dose relationship and the radial geometry, the thermal dose gradients are very steep. 38 For the 5-15 min heats under the conditions tested, the difference between the t 43 ϭ300 and 600 min contour was usually less than 1 mm. Figure 2 shows the maximum lesion diameters from heating experiments with selected diameters of CC and ICDC interstitial ultrasound applicators. Figures 2͑a͒ and 2͑b͒ plot maximum lesion diameter as a function of calculated acoustic power per centimeter of transducer length in ex vivo bovine liver and beef muscle, respectively. Each data point is the average of three experimental lesions measurements with the standard deviation given as error bars. Figures 2͑c͒ and  2͑d͒ show the results of simulations performed with parameters matched to the corresponding experimental conditions as line series. For comparison with the simulated results, the experimental data points from ͑a͒ and ͑b͒ are also shown without connecting lines in ͑c͒ and ͑d͒, respectively.
III. RESULTS
In order to better visualize the influence of applicator diameter on power requirements. Figures 3͑a͒ and 3͑b͒ show the same lesion data as Figs. 2͑a͒ and 2͑b͒, but with the lesion diameters plotted as a function of the acoustic power per applicator surface area ͑intensity͒. The surface area is defined using the length of the transducer and either the outer radius of the applicator for ICDC applicators or of the catheter for CC applicators. Figure 4 shows lesion diameters as a function of ultrasonic heating time calculated for these applicators in four tissue sites of clinical interest. Plotted are simulated lesion sizes in ͑a͒ prostate, ͑b͒ normal liver, ͑c͒ uterine fibroid, and ͑d͒ brain. The same four applicators described in Table I were used in each tissue type, with the tissue parameters as described in Table II . In each case the simulation controlled the applied power to the applicator so that the maximum tissue temperature was maintained at 90°C or less for the duration of the heating time. In order to approximate realistic limitations on the amount of power delivered to these small transducers, the control system was constrained to a maximum of 30 W of electrical power per channel for each heat. After power off the simulations were continued for 5 min with the applicator removed to allow for the accumulation of thermal dose during cool down. Figure 5 depicts simulated radial temperature contours after 1, 3, and 5 min of heating for ͑a͒ ICDC and ͑b͒ CC applicators in perfused prostate. The simulations were performed as described above, with the maximum tissue temperature controlled to 90°C. The temperature are plotted as a function of distance from the applicator outer surface, with a normal tissue temperature of 37°C. Three lines ͑1, 3, and 5 min͒ are plotted for each applicator, with tissue temperature at positions greater than 5 mm increasing with time.
Figures 6͑a͒ and 6͑b͒ visually bracket the typical lesions from the applicators used in this study. Figure 6͑a͒ shows a typical lesion from a 4.0 mm OD applicator at moderate acoustic output levels ͑5-15 W/cm͒. In this lesion, a circular area of tissue is not coagulated in the center ͑around the point of applicator insertion͒ due to applicator cooling effects. Smaller applicators at low acoustic output levels ͑2-7 W/cm͒ produce similar but smaller lesions. Figure 6͑b͒ shows a typical lesion in liver from a 4.0 mm OD applicator supplying high acoustic power output ͑10-20 W/cm͒. The key characteristics of this lesion are visible areas of tightly coagulated or charred tissue and tissue coagulated up to the center of the lesion. The region of ''tight'' coagulation is offset from the applicator by a thin rim of normal looking coagulated tissue due to cooling from the applicator pushing the maximum temperature away from the applicator surface. Smaller OD applicators at moderate acoustic power levels ͑5-15 W/cm͒ produce similar but smaller lesions. 
IV. DISCUSSION AND CONCLUSIONS
A primary goal of this study was to determine whether larger diameter interstitial applicators could produce significantly larger lesions than similar smaller devices. In order to quantify these differences, we compared the lesions formed from large ͑4.0 mm OD͒ applicators to smaller ͑2.2 to 2.4 mm OD͒ applicators using ex vivo tissue models and biothermal simulations. The smaller applicator diameters represented sizes appropriate for traditional interstitial use, such as in single or multi-applicator implants of deep-seated sites via a percutaneous approach, or also for endoscopic or laparoscopic insertion. The large size interstitial applicators would, in our opinion, be more suitable for single applicator heating strategies in sites where access is not limited by sensitive intervening tissue or those sites directly accessible via laparoscopic or endoscopic approaches. Although not studied in this article, any of these applicator configurations could be modified with multiple transducers to provide axial control or sectored transducers to provide angular control or directionality. [43] [44] [45] Even though the smaller applicators are more attractive from a clinical perspective, larger applicators present several potential advantages. While cylindrical transducers of equal frequency have the same thickness, larger diameter tubes have higher ratios of inner surface area to volume than smaller ones. This is especially important for internally cooled applicators, since it enables more energy to be transferred out of the transducer by convection on the inner surface. A higher cooling rate allows more electrical energy to be applied without overheating the transducer or the adjacent tissue, pushing the maximum temperature away from the surface of the transducer and expanding the thermal penetration ͓Figs. 5 and 6͑a͔͒. In practice, reducing the cooling water flow rate near the end of the heating duration would allow the treatment to complete near the applicator. Similarly, more power can be applied to larger transducers while maintaining the same outer surface acoustic intensity ͑W/cm 2 ͒ due to their higher outer surface area. Too high of an acoustic intensity may char or desiccate the tissue near the transducer surface, producing a layer of very high acoustic attenuation that would reduce ultrasound propagation into the tissue. By maintaining the same surface intensity with higher applied power, larger transducers in principle allow more energy to be deposited into the tissue during the course of a heat. Figure 5 indicates some of the differences in cooling dynamics between large and small and ICDC and CC applicators. The temperatures adjacent to the applicator are cooler in the case of the CC applicators. Since the transducers are seated deeper in the applicator, the resistive heating of the transducers does not contribute significantly to a temperature rise at the catheter ͑applicator͒ surface. For ICDC applicators, the interaction between transducer resistive heating, transducer convective cooling, and ultrasound power deposition in the tissue makes for a more complex dynamic near the applicator surface. In part because in these simulations the cooling flow was started at the same time as power was turned on, in the case of the 2.2 mm OD ICDC applicator, the maximum tissue temperature occurred at the applicator surface at the 1 min time point ͓Fig. 5͑a͔͒. At later times, the cooling pushed the maximum temperature away from the surface. The transducer in the larger OD ICDC applicator did not heat up as much due to its larger volume and greater cooling surface area, keeping the maximum tissue temperature away from the transducer surface at all times.
ICDC and CC applicators of large and small OD were evaluated using lesion studies in beef muscle and freshly excised bovine liver tissue models. Even though ex vivo tissues obviously lack perfusion, they can be useful for performance comparisons of different applicators and analysis of certain parameters. However, it is important to understand that the results are only similar to in vivo lightly perfused tissue such as porcine thigh muscle and not highly perfused tissues such as normal brain and liver. 44, 45 As illustrated in Fig. 6͑b͒ , we observed regions of ''tightly'' coagulated tissue in the areas of highest thermal dose in lesions formed from high power heats in both tissue models. The tightly coagulated tissue regions appeared to be more desiccated and constricted than normally coagulated tissue. The formation of tightly coagulated zones with significantly greater attenuation would have a significant and negative effect on the maximum size of ultrasound lesions attainable with these interstitial devices. Future design of appropriate power application schemes may be able to limit the maximum tissue temperature, reducing the amount of tight coagulation and maximizing the lesion size. Attenuation measurements also indicated that the acoustic attenuation of the normal beef muscle used was at least double the value of the freshly excised liver. We believe that this led to a more rapid temperature rise from ultrasound absorption close to the applicator, resulting in a more rapid onset of tight coagulation and a subsequent reduction in potential lesion size. As seen in Figs. 2͑a͒ and 2͑b͒ , applicators capable of making 3.5 to 5.0 cm lesions in liver made 3.0 to 3.5 cm lesions in beef under equivalent conditions.
Figures 2͑a͒ and 2͑b͒ illustrate that larger diameter applicators did make larger lesions than the smaller diameter devices at higher acoustic output power levels. The 4.0 mm OD applicators made the largest lesions in the 10-20 W/cm range. At low power levels ͑2-10 W/cm͒, the acoustic surface intensity of these larger applicators was too low to overcome the cooling effect of the circulating water, resulting in significant regions of preserved tissue within the center of the lesion. Since the smaller applicators had higher surface intensity and lower cooling rates, they made lesions of comparable size in the 2-10 W/cm range without a preserved region in the center.
However, at acoustic power levels greater than 10 W/cm in liver ͓Fig. 2͑a͔͒, the lesion sizes for the 2.2 mm OD ICDC applicators decreased with increasing power. This effect corresponded with the onset of tightly coagulated zones in the lesions, as seen in Fig. 6͑b͒ . We expected that the lesions from the 2.4 mm OD CC applicators would also decrease with increasing power, but the external catheters were unable to withstand the higher powers required for this test. This effect was not seen in ex vivo liver with larger applicators, and lesion size continued to grow with increasing power. In beef muscle ͑Fig. 2b͒, similar trends between large and small applicators were seen. However, the effect of tight tissue coagulation was even more pronounced in this higher attenuation tissue, as both large and small applicators produced less thermal penetration at higher power levels. In the beef muscle model used for this study, tightly coagulated zones were seen in lesions from all applicators in the 10-20 W/cm range. FIG. 6 . Ultrasound lesions formed in ex vivo liver. Lesion ͑a͒ was formed using 7 W/cm acoustic power from a 4.0 mm OD CC applicator for 10 min. The white arrow points to tissue at the lesion center preserved by using a high cooling water flow rate in the applicator. Lesion ͑b͒ was formed using 12 W/cm of acoustic power from a 4.0 mm OD CC applicator for 10 min. White arrows indicate regions of ''tight'' coagulation.
Figures 3͑a͒ and 3͑b͒ present the lesion data as a function of surface intensity rather than acoustic power per unit length. If tight tissue coagulation were limiting lesion size, then applicators with the same intensity would make nearly the same size lesions, corrected for the applicator diameter. In addition, lesion size would stop growing at the same power per surface area level. However, the ICDC series in Figs. 3͑a͒ and 3͑b͒ shows that the significantly increased cooling rate in the larger applicators complicates this analysis. The larger ICDC applicators made significantly larger lesions than the smaller applicators at the same acoustic intensity levels. Another interesting effect seen in Fig. 3͑b͒ is that the lesion sizes from all four applicators converge at higher acoustic intensities. At these levels, it is likely that sound-blocking, tightly coagulated regions formed early in the heats, reducing ultrasonic power deposition deep into the tissue. It is also likely that the same effect would be seen at higher intensity levels in the lower attenuation liver model. As mentioned earlier, we believe that specific power application strategies could be used to overcome or minimize this problem.
A second goal of this study was to compare the lesion sizes from CC and ICDC applicators for similar diameter devices. The cooling water flow configuration in CC applicators is more efficient at keeping the transducers and tissue adjacent to the applicator cool. The sacrifices are that the transducers must be smaller relative to the applicator diameter to allow cooling water to travel over their outer surfaces and that the catheter material absorbs some of the acoustic energy before it reaches the tissue. Figures 2 and 3 illustrate that applicator type ͑ICDC or CC͒ was not as significant of a factor as diameter, given that required power levels were attainable. The melting point of the catheter material limited the amount of power that could be delivered through the CC applicators relative to their ICDC counterparts. However, the higher power levels possible with ICDC applicators did not make larger lesions due to cooling limitations and the resulting onset of tight tissue coagulation.
The line series in Figs. 2͑c͒ and 2͑d͒ represent simulated lesion sizes under the same conditions as the experimental data. By accounting for higher attenuation values at higher thermal doses, the simulation results matched the experimental data well. This is a departure from what we have done in prior simulation studies, but the continued rise of acoustic attenuation at thermal doses above t 43 ϭ10 7 and temperatures greater than 75°C is supported by unpublished transmission attenuation measurements done in our lab and by recent studies showing greater increases in attenuation due to thermal treatment. 34, 35 In order to investigate differences in lesion size in various types of perfused tissues, we performed a series of thermal simulations. We selected four ''tissue'' types to bracket perfusion and attenuation ranges of common tissues and to represent some sites of current clinical interest for thermal coagulation. Figures 4͑a͒-4͑d͒ show that tissue perfusion was clearly the largest factor in predicting lesion size. The largest lesions were seen in low perfusion tissues such as ͑a͒ prostate and ͑c͒ uterine fibroid ͑3.9 to 4.7 cm lesion for ϭ2 kg/m 3 •s), and the smallest in the highly perfused ͑b͒ normal liver ͑2.8 to 3.2 cm lesion for ϭ15 kg/m 3 •s). The acoustic attenuation and/or frequency was significantly less of a factor in the ranges studied. Note that the results in normal liver and brain do not necessarily represent performance in tumors, where blood perfusion and attenuation may be significantly different. As seen in the ex vivo studies discussed above, the simulations show that the 4.0 mm OD applicators are able to make consistently larger lesions than the smaller interstitial applicators. The higher cooling rates and lower intensities for the same energy deposition from the larger applicators moves the maximum temperature farther away from the applicator, effectively creating a larger hot source.
In practice, blood flow in tumors will not be uniform as assumed in these simulations. Regions of heterogeneous perfusion and the presence of thermally significant blood vessels in the treatment volume could significantly affect the size and shape of lesions produced with these applicators. However, due to increased radial penetration and potential for axial and angular control, interstitial ultrasound may be less sensitive to these effects than radiofrequency, microwave, or laser ablation. In addition, invasive or noninvasive temperature monitoring could be used to control the angular and axial power deposition of ultrasound applicators to compensate for heterogeneities.
Clinical considerations such as risk of complications associated with applicator diameter, percutaneous versus endoscopic or laparoscopic access, and single versus multiple applicator implants are highly dependent on the disease and treatment site. In situations where larger diameter applicators can be tolerated, 4.0 mm OD CC or ICDC devices provide greater radial lesion penetration, higher power deposition, and lower maximum temperatures compared to 2.2 or 2.4 mm OD devices. For example, considering endoscopic treatment of fibroids, results shown in Fig. 4͑c͒ indicate that using a 4.0 mm OD CC rather than a 2.4 mm OD CC applicator would result in a 37% increase in treatment volume. This is in contrast to deep brain implants, for example, in which clinical consideration may mandate the smallest possible applicator diameter. Finally, in applications such as perineal prostate implants, multiple smaller applicators may be preferred to a single large applicator to maximize treatment volume and conformity. 
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